CA2137431A1 - Treatment of diabetes by administration of myo-inositol - Google Patents

Treatment of diabetes by administration of myo-inositol

Info

Publication number
CA2137431A1
CA2137431A1 CA002137431A CA2137431A CA2137431A1 CA 2137431 A1 CA2137431 A1 CA 2137431A1 CA 002137431 A CA002137431 A CA 002137431A CA 2137431 A CA2137431 A CA 2137431A CA 2137431 A1 CA2137431 A1 CA 2137431A1
Authority
CA
Canada
Prior art keywords
composition
inositol
myo
total
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002137431A
Other languages
English (en)
French (fr)
Inventor
Harry L. Greene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2137431A1 publication Critical patent/CA2137431A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/37Sugar alcohols
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/801Peptide sweetners

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002137431A 1993-12-22 1994-12-06 Treatment of diabetes by administration of myo-inositol Abandoned CA2137431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17381493A 1993-12-22 1993-12-22
US08/173,814 1993-12-22

Publications (1)

Publication Number Publication Date
CA2137431A1 true CA2137431A1 (en) 1995-06-23

Family

ID=22633617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137431A Abandoned CA2137431A1 (en) 1993-12-22 1994-12-06 Treatment of diabetes by administration of myo-inositol

Country Status (6)

Country Link
US (1) US5763392A (OSRAM)
EP (1) EP0659349A1 (OSRAM)
JP (1) JPH07223939A (OSRAM)
AU (1) AU8163394A (OSRAM)
CA (1) CA2137431A1 (OSRAM)
TW (1) TW282398B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
NO962728A (no) * 1996-06-27 1997-11-17 Jan Oxholm Gordeladze Energidrikk
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CA2284738C (en) * 1997-03-27 2008-12-23 Michael J. Sole Nutritional composition for improvements in cell energetics
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
CA2334222C (en) * 1998-06-05 2010-02-09 Technion Research And Development Foundation Ltd. Insulin supplemented infant formula
JP2002542295A (ja) * 1999-04-27 2002-12-10 インスメッド ファーマシューティカルズ, インコーポレイテッド 哺乳動物において、インスリン感受性およびグルコース代謝を改善する組成物および方法
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US20040110693A1 (en) * 2001-03-02 2004-06-10 Friedrich Trepel Agent for treating diabetes mellitus
US20040097467A1 (en) 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
JP2004203863A (ja) * 2002-12-09 2004-07-22 Taisho Pharmaceut Co Ltd 抗糖尿病用組成物
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
CA2545584C (en) 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
AU2005306686B2 (en) * 2004-11-17 2011-06-02 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
JP2006213684A (ja) * 2005-02-07 2006-08-17 Hokko Chem Ind Co Ltd インスリン抵抗性改善に用いられる組成物及び健康用食品
JP2007051132A (ja) * 2005-07-19 2007-03-01 Hokkaido Sugar Co Ltd イノシトールを成分とする食用組成物または医薬組成物
US7763650B2 (en) * 2006-03-15 2010-07-27 Medipharma S.A. Pharmaceutical compound and method
MX2010000660A (es) * 2009-12-11 2011-06-14 Abbott Lab Soluciones de rehidratacion oral que comprenden dextrosa.
ITMI20110445A1 (it) * 2011-03-22 2012-09-23 Lo Li Pharma Srl Formulazione farmaceutica comprendente inositolo.
TWI582110B (zh) * 2011-07-01 2017-05-11 Shiseido Co Ltd Platelet-derived growth factor-BB produces hyperactivity agents, and is associated with leaf-derived stem cell-producing accelerators, stem cell stabilizers, and dermal regenerators
ES2604110T3 (es) 2011-07-01 2017-03-03 Shiseido Company, Ltd. Activador de la producción del factor de crecimiento derivado de plaquetas-BB, y activador de la producción de células madre mesenquimatosas, estabilizador de células madre y regenerador de la dermis comprendiendo cada uno el mismo
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20140328970A1 (en) * 2013-05-03 2014-11-06 Mead Johnson Nutrition Company Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof
CN106659739B (zh) 2014-08-08 2021-06-18 雀巢产品有限公司 维生素d和锌的组合产品及其用途
EP3177278A1 (en) 2014-08-08 2017-06-14 Nestec S.A. Vitamin b2 and its use
MX374378B (es) * 2014-08-08 2025-03-06 Soc Des Produits Nestle S A Star Mioinositol y probioticos, y uso de estos.
ES2792865T3 (es) * 2014-08-08 2020-11-12 Nestle Sa Mioinositol y probióticos y usos
CA2953030C (en) * 2014-08-08 2023-10-10 Nestec S.A. Myo-inositol and one or more probiotic and use thereof
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US10525016B2 (en) 2015-06-03 2020-01-07 Mead Johnson Nutrition Company Nutritional compositions containing an elevated level of inositol and uses thereof
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
US11898184B2 (en) * 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
CA3118583C (en) 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
CN111772022A (zh) * 2020-05-25 2020-10-16 唐传生物科技(厦门)有限公司 一种低gi健康糖及其制备方法和用途
WO2021259938A1 (en) * 2020-06-22 2021-12-30 Société des Produits Nestlé S.A. Compositions comprising myo-inositol and their use in the prevention of post partum haemorrhage (pph)
MX2023002627A (es) 2020-09-04 2023-03-17 Nestle Sa Composiciones y metodos para proporcionar beneficios de salud en un animal.
WO2023183767A1 (en) * 2022-03-21 2023-09-28 Abbott Laboratories Methods and compositions for increasing insulin sensitivity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
US4921877A (en) * 1986-10-27 1990-05-01 Abbott Laboratories Liquid nutritional formula for glucose intolerance
CA2047686C (en) * 1989-03-08 2000-09-05 Joseph Larner Dietary supplement for insulin-resistant diabetics
WO1991014435A1 (en) * 1990-03-19 1991-10-03 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes

Also Published As

Publication number Publication date
US5763392A (en) 1998-06-09
TW282398B (OSRAM) 1996-08-01
EP0659349A1 (en) 1995-06-28
JPH07223939A (ja) 1995-08-22
AU8163394A (en) 1995-06-29

Similar Documents

Publication Publication Date Title
US5763392A (en) Treatment of diabetes by administration of myo-inositol
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Scientific opinion on the essential composition of infant and follow‐on formulae
Dobbelaere et al. Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria
Surwit et al. Metabolic and behavioral effects of a high-sucrose diet during weight loss
Bonner et al. Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates
Fusch et al. Neonatology/paediatrics–Guidelines on parenteral nutrition, Chapter 13
Lagua et al. Nutrition and diet therapy reference dictionary
Liu et al. Time and intervention effects of daily almond intake on the changes of lipid profile and body composition among free-living healthy adults
US20010022980A1 (en) Dietary supplement for individuals under stress
MXPA05003088A (es) Composiciones nutricionales enriquecidas en leucina.
Schulz et al. Nutrient intake and food consumption of adolescents and young adults with phenylketonuria
BRPI0620244A2 (pt) uso de uma fração de lipìdeos, composição, formulação em pó antialérgica para bebe, e, uso de uma composição
CN104922115A (zh) 含有氨基酸组合物的抗疲劳剂
Tanner et al. Nutrient intake in lysinuric protein intolerance
Lee et al. Essential fatty acid deficiency in parenterally fed preterm infants
Wadhwa et al. Metabolic consequences of feeding frequency in man
Churella et al. Growth and protein status of term infants fed soy protein formulas differing in protein content.
Ayling Clinical biochemistry of nutrition
Jones et al. Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra
Lanting et al. Lipids in infant nutrition and their impact on later development
Roulet Protein‐energy malnutrition in cystic fibrosis patients
TW201507627A (zh) 包含乳清和經水解之酪蛋白之營養組成物及彼之用途
JP2016102064A (ja) 脂質代謝促進剤
TWI749050B (zh) 包含選自瓜胺酸、白胺酸、半胱胺酸、牛磺酸、麩胺酸及天冬胺酸所成群組的1種或2種以上之胺基酸與中鏈脂肪酸及中鏈脂肪酸酯之任一者或兩者之組成物用於人攝取促進酮體生成之使用
Igarashi et al. Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet

Legal Events

Date Code Title Description
FZDE Discontinued